冻干粉 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
AHCC is widely used in the world and many people use it for general health maintenance and treatment of various diseases. It is often used as a complementary and alternative medicine (CAM) for immune support, as reports in animal and clinical settings have indicated that AHCC is associated with an enhanced response to infection and increased survival. AHCC is in some cases also used by those undergoing conventional cancer therapy (e.g. chemotherapy) for its reported immunomodulatory functions. In Japan, AHCC is the 2nd most popular complementary and alternative medicine used by cancer patients. Agaricus blazei supplements are the most popular, outpacing AHCC use by a factor of 7:1.
ADAM17 is an 824-amino acid polypeptide. ADAM17 has multidomain structure that includes a pro-domain, a metallo-protease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic tail. The metalloprotease domain is responsible for the enzyme's catalytic activity, cleaving membrane-bound proteins, including cytokines like TNF-alpha, to release their soluble forms. The disintegrin and cysteine-rich domains are implicated in cell adhesion and interaction with integrins, while the transmembrane domain anchors the protein in the membrane. The cytoplasmic tail is involved in intracellular signaling and protein-protein interactions. ADAM17's activity is tightly regulated through multiple mechanisms, including the removal of its pro-domain and interactions with regulatory proteins such as TIMPs (tissue inhibitors of metalloproteinases).
=== Stable isotopes === Stable lutetium can be used as catalysts in petroleum cracking in refineries and can also be used in alkylation, hydrogenation, and polymerization applications. Lutetium aluminium garnet (Al5Lu3O12) has been proposed for use as a lens material in high refractive index immersion lithography. Additionally, a tiny amount of lutetium is added as a dopant to gadolinium gallium garnet, which was used in magnetic bubble memory devices. Cerium-doped lutetium oxyorthosilicate is currently the preferred compound for detectors in positron emission tomography (PET). Lutetium aluminium garnet (LuAG) is used as a phosphor in light-emitting diode light bulbs. Lutetium tantalate (LuTaO4) is the densest known stable white material (density 9.81 g/cm3) and therefore is an ideal host for X-ray phosphors. The only denser white material is thorium dioxide, with density of 10 g/cm3, but the thorium it contains is radioactive. Lutetium is also a compound of several scintillating materials, which convert X-rays to visible light. It is part of LYSO, LuAG and lutetium iodide scintillators. Research indicates that lutetium-ion atomic clocks could provide greater accuracy than any existing atomic clock.
While the 2018 United States farm bill removed hemp and hemp extracts (including CBD) from the Controlled Substances Act, the marketing and sale of CBD formulations for medical use or as an ingredient in dietary supplements or manufactured foods remains illegal under FDA regulation, as of 2024.
the stored elastic strain energy which is released as a crack grows. This is the thermodynamic driving force for fracture. the dissipated energy which includes plastic dissipation and the surface energy (and any other dissipative forces that may be at work). The dissipated energy provides the thermodynamic resistance to fracture. Then the total energy is:
Sources: en.wikipedia.org
Vitamin E is a group of eight compounds related in molecular structure that includes four tocopherols and four tocotrienols. The tocopherols function as fat-soluble antioxidants which may help protect cell membranes from reactive oxygen species. Vitamin E is classified as an essential nutrient for humans. Various government organizations recommend that adults consume between 3 and 15 mg per day, while a 2016 worldwide review reported a median dietary intake of 6.2 mg per day. Sources rich in vitamin E include seeds, nuts, seed oils, peanut butter, vitamin E–fortified foods, and dietary supplements. Symptomatic vitamin E deficiency is rare, usually caused by an underlying problem with digesting dietary fat rather than from a diet low in vitamin E. Deficiency can cause neurological disorders. Tocopherols and tocotrienols both occur in α (alpha), β (beta), γ (gamma), and δ (delta) forms, as determined by the number and position of methyl groups on the chromanol ring. All eight of these vitamers feature a chromane double ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals, and a hydrophobic side chain that allows for penetration into biological membranes. Both natural and synthetic tocopherols are subject to oxidation, so dietary supplements are esterified, creating tocopheryl acetate, (or other forms such as succinate or palmitate) for stability purposes.
Mary Margaret Dalligan, lately Home Care Worker, London Borough of Southwark. For services to the community. Celeste Dandeker, Artistic Director, Candoco. For services to Dance and to Disabled People. Peter Daniel, Chairman, Ridgemond Training, Stevenage, Hertfordshire. For services to Training and Young People. Wasim Darr, President, UK Islamic Mission (Southern Region). For services to Community Relations. Harriet Emily Rhys-Davies. For political and public service. Irene Joyce Davies. For services to the community in Pantymwyn, Flintshire. Joyce Mary Davies. For services to the British Red Cross Society in Shropshire. Catherine Elizabeth Dawson, Chief Administrative Dental Officer, Grampian Health Board. For services to Dentistry. Geoffrey Michael Day. For services to the Oil Industry. Hugh Ludlow de Quetteville. For charitable services. Simon Patrick Dell, Constable, Devon and Cornwall Constabulary. For services to the Police. William Ernest Denny. For services to Soldiers', Sailors' and Airmen's Families Association in Warwickshire. Royland Charles Derham, General Secretary, the TS Vindicatrix Association. For services to the Merchant Navy. Joyce Muriel Dewey. For services to the community in Lymington, Hampshire. Frederick Gains Dobson. For services to the Ex-Service Fellowship Centres. Ingnd Julia Dodd. For political services. John Doherty. For services to Disabled ex-Servicemen and Women. Maurice Francis Donaghy, Assistant Controller, The Stamp Office, Board of Inland Revenue. Hilda Donaldson. For services to Education. Margaret Agnes Donaldson.
== Side effects == One of the most common side effects of spironolactone is frequent urination. Other general side effects include dehydration, hyponatremia (low sodium levels), mild hypotension, ataxia (muscle incoordination), drowsiness, dizziness, dry skin, and rashes. Because of its antiandrogenic activity, spironolactone can cause breast tenderness, gynecomastia (breast development), feminization in general, and demasculinization, as well as sexual dysfunction including loss of libido and erectile dysfunction, although these side effects are usually confined to high doses. At very high doses (400 mg/day), spironolactone has also been associated with testicular atrophy and reversibly reduced fertility, including semen abnormalities, such as decreased sperm count and motility in men, but such doses of spironolactone are rarely used clinically. In women, spironolactone can cause menstrual irregularities, breast tenderness, and breast enlargement. Aside from these adverse effects, the side effects of spironolactone in women taking high doses are minimal, and it is well tolerated. A potential side effect of spironolactone is hyperkalemia (high potassium levels), which in severe cases, can be life-threatening. Hyperkalemia can present as a normal anion-gap metabolic acidosis. The addition of spironolactone to loop diuretics in people with heart failure reportedly was associated with a higher risk of hyperkalemia and acute kidney injury. Spironolactone may put people at a heightened risk for gastrointestinal issues such as nausea, vomiting, diarrhea, cramping, and gastritis.
=== Extracellular signalling and neurotransmission === Cells secrete ATP to communicate with other cells in a process called purinergic signalling. ATP serves as a neurotransmitter in many parts of the nervous system, modulates ciliary beating, affects vascular oxygen supply etc. ATP is either secreted directly across the cell membrane through channel proteins or is pumped into vesicles which then fuse with the membrane. Cells detect ATP using the purinergic receptor proteins P2X and P2Y. ATP has been shown to be a critically important signalling molecule for microglia - neuron interactions in the adult brain, as well as during brain development. Furthermore, tissue-injury induced ATP-signalling is a major factor in rapid microglial phenotype changes.
Force amplification in the braking system of most motor vehicles. Used in artesian wells, water towers, and dams. Scuba divers must understand this principle. Starting from normal atmospheric pressure, about 100 kilopascal, the pressure increases by about 100 kPa for each increase of 10 m depth. Usually Pascal's rule is applied to confined space (static flow), but due to the continuous flow process, Pascal's principle can be applied to the lift oil mechanism (which can be represented as a U tube with pistons on either end).
Sources: en.wikipedia.org
Homology - the structure is similar between the two species because of shared ancestry and common genetics. Convergence - the structure is similar between the two species because of independent adaptation to common environmental pressures. Understanding which characteristics and structures belong to each type is an important part of understanding plant evolution. The evolutionary biologist relies on the plant morphologist to interpret structures, and in turn provides phylogenies of plant relationships that may lead to new morphological insights.
The Dexcom CGM is a continuous glucose monitoring system developed by Dexcom, Inc., a company specializing in glucose monitoring technology for individuals with diabetes. Several iterations of the Dexcom CGM wearable device have been released, beginning with the Dexcom Short-Term Sensor (STS), followed by the Dexcom Seven and Dexcom Seven Plus. Later models include the Dexcom G4, Dexcom G5, Dexcom G6, and Dexcom G7. The most recently released model, Stelo by Dexcom, is a more affordable option designed for individuals with type 2 diabetes. Dexcom was founded in 1999 by John Burd and released its first CGM, the Dexcom STS, in 2006 following U.S. Food and Drug Administration (FDA) approval. As of 2025, only the Dexcom G6, Dexcom G7, and Stelo remain available.
Actin filaments are often rapidly assembled and disassembled, allowing them to generate force and support cell movement. Assembly classically occurs in three steps. First, the "nucleation phase", in which two to three G-actin molecules slowly join to form a small oligomer that will nucleate further growth. Second, the "elongation phase", when the actin filament rapidly grows by the addition of many actin molecules to both ends. As the filament grows, actin molecules are added to the (+) end of the filament around 10 times faster than to the (−) end, and so filaments tend to primarily grow at the (+) end. Third, the "steady-state phase", where an equilibrium is reached as actin molecules join and leave the filament at the same rate, maintaining the filament's length. While the filament's length remains constant in the steady-state phase, new molecules are constantly being added to the (+) end and falling off the (−) end, a phenomenon called "treadmilling" as a given actin molecule would appear to move along the strand. In isolation, whether a filament will grow or shrink, and how quickly, are determined by the concentration of G-actin around the filament; however, in cells, the dynamics of actin filaments are heavily influenced by various actin-binding proteins.
== Side effects == Side effects of oral minoxidil may include salt retention, water retention and edema, rapid heartbeat, dizziness, lightheadedness, headaches, and hypertrichosis (excessive hair growth). Topically applied minoxidil is generally well-tolerated, but common side effects include itching of the eyes, general itching, irritation at the treated area, and unwanted hair growth elsewhere on the body. Alcohol and propylene glycol present in some topical preparations may dry the scalp, resulting in dandruff and contact dermatitis. Sublingual minoxidil may have reduced side effects with retained effectiveness compared to oral minoxidil. This is due to less minoxidil sulfate being formed during first-pass metabolism and due to local activation of minoxidil into minoxidil sulfate within hair follicles. In a preliminary clinical trial, no adverse effects or changes in blood pressure occurred with low-dose sublingual minoxidil. Oral minoxidil has been implicated in causing pericarditis, pericardial effusion, and pleural effusion. Cardiac tamponade secondary to pericardial effusion, which can be life-threatening, is also known to occur. Pericardial effusion has been found to occur in about 3% of people at hypertension doses. This is usually associated with impaired renal function, connective tissue disease, uremic syndrome, congestive heart failure, or marked fluid retention, though cases without these potential risk factors have also been reported.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.